Psyence Biomedical Ltd. - Common Shares (PBM)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 13, 2026Investment Snapshot
- Trading 81% below Graham Number ($28.94) — significant margin of safety
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 8.5% — below-average profitability
Psyence Biomedical Ltd. - Common Shares (PBM) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $3 million . Key value metrics: P/E ratio 3.1, P/B ratio 0.27, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Psyence Biomedical Ltd. - Common Shares — Fundamental Analysis Summary
Psyence Biomedical Ltd. - Common Shares (PBM) is trading 81% below its Graham Number of $28.94 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 3.1x.
On financial health, PBM shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and modest return on equity of 8.5% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.88.
StockPik's composite Value Score for PBM is 80/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PBM shows earnings growing at 102%.